167
Participants
Start Date
September 30, 2006
Primary Completion Date
December 31, 2008
Study Completion Date
December 31, 2008
NucleomaxX
36 g sachet taken orally three times daily
NucleomaxX placebo
36 g placebo sachet taken orally three times daily
Beth Israel Med. Ctr., ACTU, New York
Cornell CRS, New York
HIV Prevention & Treatment CRS, New York
Trillium Health ACTG CRS, Rochester
Unc Aids Crs, Chapel Hill
Duke Univ. Med. Ctr. Adult CRS, Durham
The Ponce de Leon Ctr. CRS, Atlanta
Vanderbilt Therapeutics CRS, Nashville
The Ohio State University Medical Center, Columbus
MetroHealth CRS, Cleveland
University of Minnesota, ACTU, Minneapolis
Rush Univ. Med. Ctr. ACTG CRS, Chicago
USC CRS, Los Angeles
Ucsd, Avrc Crs, San Diego
Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu
University of Washington AIDS CRS, Seattle
Alabama Therapeutics CRS, Birmingham
UCLA CARE Center CRS, Los Angeles
Stanford CRS, Palo Alto
Harbor-UCLA Med. Ctr. CRS, Torrance
University of Colorado Hospital CRS, Aurora
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis
Johns Hopkins Adult AIDS CRS, Baltimore
NY Univ. HIV/AIDS CRS, New York
Univ. of Rochester ACTG CRS, Rochester
Univ. of Cincinnati CRS, Cincinnati
Case CRS, Cleveland
Pitt CRS, Pittsburgh
The Miriam Hosp. ACTG CRS, Providence
Puerto Rico-AIDS CRS, San Juan
National Institute of Allergy and Infectious Diseases (NIAID)
NIH